http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3782492-D1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f84747e8d08b1023763356d0e7d1db68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18698187940245cef82d2e72c284d50f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2984 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate | 1987-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d83e10cb1232509da09d2fc5c6667a8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_447426184b1ceea738cb3fb696ebf861 |
| publicationDate | 1992-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-3782492-D1 |
| titleOfInvention | LIPOSOME ANTHRACHINONE MEDICINE COMPOSITION AND PRODUCTION. |
| abstract | A novel anthraquinone/liposome compsn. comprises: (a) liposomes contg. at least 0-1 mole % of a lipophilic free-radical scavenger (I), (b) entrapped in the lipid bilayer region of the liposomes, an anthraquinone drug (II) having quinone and hydroquinone functionalities on adjacent anthracene rings and (c) a trihydroxamic acid chelating agent (III) at a concn. in molar excess of ferric iron in the compsn. Pref. (II) is an anthracycline glycoside, e.g. doxorubicin (DXR) or an analogue, deriv. or salt. (I) is pref. alpha-tocopherol or an analogue, deriv. or ester. (III) is pref. ferrioxamine. The liposomes pref. contain 20-50 mole % cholesterol and 10-50 mole % of a negatively charged phospholipid selected from phosphatidyl glycerol, phosphatidylinositol and phosphatidylserine. Also claimed in an aq. suspension of liposomes whose sizes are predominantly 0.05-0.25 microns and which contain at least 2.5 mole % DXR or analogue or deriv. for use in a method of treating a prim. or sec. neoplasm of the liver by administering the compsn. to the patient via the bloodstream. Also claimed is DXR entrapped in liposomes for use in a method of reducing the incidence of nausea and alopecia in humans produced by bolus i.v. administration of a therapeutically effective amt. of free DXR by administering the liposomes by fast-drip to the bloodstream. |
| priorityDate | 1985-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.